Drug Target Review

APRIL 7, 2025

Advancements in screening technologies for small-molecule drug discovery including cellular assays, computational screening, and biophysics-based methods enhanced by structural biology breakthroughs have improved screening hit rates and facilitated the identification of drug candidates for previously undruggable targets.

Fragment Screening 52

Fragment Screening Drugs Small Molecule Biophysical Assays 52

Drug Target Review

NOVEMBER 1, 2023

The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. We support the drug discovery projects of the CCDD with assay development and screening, biophysics, structural biology and recombinant protein production.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

Drug Target Review

JANUARY 16, 2025

Phase III trials for MK-0616 commenced in the second half of 2023. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. These drugs, including grazoprevir and vaniprevir, were the result of macrocyclisation of acyclic precursors. 8 Why are there not more macrocyclic drugs? Ballantyne CM, Banka P, Mendez G, et al.

Drug Development 52

Drug Development Small Molecule Drugs FDA Approval 52